-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $36

Benzinga·11/10/2026 15:58:17
Listen to the news
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $35 to $36.